MEDIPOST announced on February 17, that the accumulated number of dosage of stem cell arthritis medicine ‘CARTISTEM^®’ exceeded 2,000 cases.

After initial launch in May 2012, ‘CARTISTEM^®’ achieved 1,000 cases in March 2014, within 22 month from launch, and achieved another thousand dosages with double speed within 11 months thereafter.

MEDIPOST anticipates that the accumulated number of dosage of ‘CARTISTEM^®’ will exceed 3,000 cases, with 8 month from now on, reflecting current trend. Entering in year 2015, ‘CARTISTEM^®’ is continuing growth momentum with 138 cases in January, which is the historical monthly record.

Jay Lee, division head of MEDIPOST’s Business Development explained that “increasing dosage of ’CARTISTEM^®’ can be regarded as more trust granted to this product by patients and the medical society, and growth in production quantity would bring enhanced productivity to the company.”